Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity

doi:10.1016/0014-2999(76)90299-5

European Journal of Pharmacology

Volume 35, Issue 1, January 1976, Pages 45-58

https://doi.org/10.1016/0014-2999(76)90299-5 Get rights and content

Abstract

The effects of local injections of drugs into terminal areas of the mesolimbic dopamine system were investigated. Bilateral administration of dopamine, but not or noradrenaline and serotonin, into the nucleus accumbens of non-pretreated rats resulted in stimulation of locomotor activity. No clear or only minor effects were seen after injections of the dopamine metabolites 3-methoxytryptamine, DOPAC and HVA and after injections of media with different pH and osmolality. d-Amphetamine proved more effective than dopamine in producing locomotor stimulation, whereas both stimulant and depressant effects were observed following injection of apomorphine into the nucleus accumbens. ET 495 and the noradrenaline agonists clonidine, phenylephrine and isoprenaline did not enhance locomotor activity, but theorphylline was effective. Pretreatment with haloperidol, but not with clozapine, significantly reduced the effects of dopamine and theophylline. Locomotor stimulation was also found following bilateral administration of dopamine, d-amphetamine and apomorphine into the tuberculum olfactorium, whereas noradrenaline, serotnin and ET 495 produced no, or rather depressant effects. These results provide further evidence for an important role of the mesolimbic dopamine system with respect to locomotor activity.

References (41)

N.-E. Andén et al.
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Europ. J. Pharmacol.
(1970)
M. Brownstein et al.
Norepinephrine and dopamine in the limbic system of the rat
Brain Res.
(1974)
H. Corrodi et al.
ET 495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors
European J. Pharmacol.
(1972)
K. Fuxe et al.
The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons
Brain Res.
(1974)
S.H. Koslow et al.
Mass fragmentographic measurement of norepinephrine, dopamine, serotonin and acetylcholine in seven discrete nuclei of the rat tel-diencephalon
Neuropharmacology
(1974)
S.J. Langer
Presynaptic regulation of catecholamine release
Biochem. Pharmacol.
(1974)
O. Lindvall et al.
Mesencephalic dopamine neurones projecting to neocortex
Brain Res.
(1974)
R. Miller et al.
Differential effects of neuroleptic drugs on amphetamine-induced stimulation of locomotor activity in 11-day-old and adult rats
Brain Res.
(1974)
M. Palkovits et al.
Choline acetyltransferase content of limbic nuclei of the rat
Brain Res.
(1974)
A.J.J. Pijnenburg et al.
Ergometrine induced locomotor activity following intracerebral injection into the nucleus accumbens
Brain Res.
(1973)

J.M. Saavedra et al.

Serotonin distribution in the limbic system of the rat

Brain Res.

(1974)

F.-A. Wiesel et al.

Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat

Europ. J. Pharmacol.

(1975)

N.-E. Andén

Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptics and anti-acetylcholine drugs

J. Pharm. Pharmacol.

(1972)

N.-E. Andén

Effects of oxotremorine and physostigmine on the turnover of dopamine in the corpus striatum and the limbic system

J. Pharm. Pharmacol.

(1974)

N.-E. Andén et al.

Evidence for dopamine receptor stimulation by apomorphine

J. Pharm. Pharmacol.

(1967)

N.-E. Andén et al.

Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system

J. Pharm. Pharmacol.

(1973)

C.L.E. Broekkamp et al.

Effecs of apomorphine on self-stimulation behavior

Psychopharmacologia

(1974)

A.R. Cools et al.

Excitation-mediating and inhibition-mediating dopamine receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data

Psychopharmacologia

(1975)

B. Costall et al.

Neuroleptic and non-neuroleptic catalepsy

Arzneim. Forsch.

(1973)

B. Costall et al.

Dopamine agonist and antagonist activities of piribedil (ET 495) and its metabolites

Naunyn-Schmiedeb. Arch. Pharmacol.

(1974)

Cited by (485)

The current state of ayahuasca research in animal models: A systematic review
2023, Progress in Neuro-Psychopharmacology and Biological Psychiatry
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting.
Review and summarise data available on ayahuasca research using animal models.
We systematically searched five databases (PubMed, Web of Science, EMBASE, LILACS and PsycInfo) for peer-reviewed studies in English, Portuguese or Spanish published up to July 2022. The search strategy included ayahuasca- and animal model-related terms adapted from the SYRCLE search syntax.
We identified 32 studies investigating ayahuasca effects on toxicological, behavioural and (neuro)biological parameters in rodents, primates and zebrafish. Toxicological results show that ayahuasca is safe at ceremonial-based doses but toxic at high doses. Behavioural results indicate an antidepressant effect and a potential to reduce the reward effects of ethanol and amphetamines, while the anxiety-related outcomes are yet inconclusive; also, ayahuasca can influence locomotor activity, highlighting the importance of controlling the analysis for locomotion when using tasks depending on it. Neurobiological results show that ayahuasca affects brain structures involved in memory, emotion and learning and that other neuropathways, besides the serotonergic action, are important in modulating its effects. Conclusions: Studies using animal models indicate that ayahuasca is toxicologically safe in ceremonial-comparable doses and indicates a therapeutic potential for depression and substance use disorder while not supporting an anxiolytic effect. Essential gaps in the ayahuasca field can still be sufficed using animal models.
Effects of repeated ayahuasca administration on behaviour and c-Fos expression in male rats exposed to the open field
2022, Behavioural Brain Research
Considering the long-lasting effects of ayahuasca on the brain and emotional processing, the objective of this study was to evaluate the behavioural and neurobiological effects of repeated ayahuasca administration in an animal model of exploratory behaviour related to novel-environment anxiety. Male Wistar rats received water, 120, 240, 480 or 3600 mg/kg of resuspended freeze-dried ayahuasca by gavage once a day for 30 days; there was also a non-manipulated homecage group. One hour after the last administration, animals were placed individually in the open field for 20 min. We analysed the weight gain, the behavioural response through a stochastic analysis, and c-Fos immunoreactive levels in the hippocampus, amygdala, pre-frontal and barrel field cortex. Ayahuasca at 120 mg/kg increased ambulation, and at 3600 mg/kg decreased vertical exploration and reduced weight gain. Aya3600 had higher c-Fos expression in regions of the hippocampus and infralimbic cortex than homecage, water or aya120 groups. Water-receiving animals had less c-Fos expression in the anterior basolateral amygdala than others groups. Our results show different behavioural effects of ayahuasca: a stimulant-like effect in small doses, and decreased activity in extreme high-dose, probably due to adverse effects. Higher activation of areas involved in emotional processing and the serotonergic pathway adds to the neurobiological literature on repeated/chronic ingestion of ayahuasca. Our data do not support an anxiolytic effect of repeated ayahuasca related to exploring new anxiogenic-environment but suggest that low ayahuasca doses should be further studied. The absence of severe impairment and behavioural syntax alteration reinforce ayahuasca safety.
Circuit and neuropeptide mechanisms of the paraventricular thalamus across stages of alcohol and drug use
2021, Neuropharmacology
Citation Excerpt :
Some drugs of abuse, notably psychostimulants and opioids, reliably induce hyperlocomotion even only after a single dose (Marie et al., 2019), and repeated use (either experimenter- or self-administered) can result in an increase in the drug's ability to enhance locomotion, a phenotype termed locomotor or behavioral sensitization (Valjent et al., 2010) that can be related to the rewarding effects of the drug. Previous work has demonstrated that both acute hyperlocomotion and locomotor sensitization rely on mesolimbic dopaminergic input to the NAc (Pijnenburg et al., 1976); however, the role of glutamatergic input to the NAc in these locomotor phenotypes has more recently been acknowledged as well (Takahata and Moghaddam, 2003). For example, electrolytic lesioning of the PVT abolishes cocaine-induced locomotor sensitization in rats (Young and Deutch, 1998).
The paraventricular nucleus of the thalamus (PVT) is a midline thalamic brain region that has emerged as a critical circuit node in the regulation of behaviors across domains of affect and motivation, stress responses, and alcohol- and drug-related behaviors. The influence of the PVT in this diverse array of behaviors is a function of its ability to integrate and convey information about salience and valence through its connections with cortical, hypothalamic, hindbrain, and limbic brain regions. While understudied to date, recent studies suggest that several PVT efferents play critical and complex roles in drug and alcohol-related phenotypes. The PVT is also the site of signaling for many neuropeptides released from the synaptic terminals of distal inputs and local neuropeptidergic neurons within. While there is some evidence that neuropeptides including orexin, neurotensin, substance P, and cocaine and amphetamine-related transcript (CART) signal in the PVT to regulate alcohol/drug intake and reinstatement, there remains an overall lack of understanding of the roles of neuropeptides in the PVT in addiction-related behaviors, especially in a circuit-specific context. In this review, we present the current status of preclinical research regarding PVT circuits and neuropeptide modulation of the PVT in three aspects of the addiction cycle: reward/acquisition, withdrawal, and relapse, with a focus on alcohol, opioids (particularly morphine), and psychostimulants (particularly cocaine). Given the PVT's unique position within the broader neural landscape, we further discuss the potential ways in which neuropeptides may regulate these behaviors through their actions upon PVT circuits.
This article is part of the special Issue on ‘Neurocircuitry Modulating Drug and Alcohol Abuse'.
Hypothalamus-skeletal muscle crosstalk during exercise and its role in metabolism modulation
2021, Biochemical Pharmacology
Physical inactivity is a major public health problem that contributes to the development of several pathologies such as obesity, type 2 diabetes and cardiovascular diseases. Regular exercise mitigates the progression of these metabolic problems and contributes positively to memory and behavior. Therefore, public health agencies have incorporated exercise in the treatment of widespread disorders. The hypothalamus, specifically the ventromedial and the arcuate nuclei, responds to exercise activity and modulates energy metabolism through stimulation of the sympathetic nervous system and catecholamine secretion into the circulation. In addition, physical performance enhances cognitive functions and memory, mediated mostly by an increase in brain-derived neurotrophic factor levels in brain. During exercise training, skeletal muscle myofibers remodel their biochemical, morphological and physiological state. Moreover, skeletal muscle interacts with other organs by the release into the circulation of myokines, molecules that exhibit autocrine, paracrine and endocrine functions. Several studies have focused on the role of skeletal muscle and tissues in response to physical activity. However, how the hypothalamus could influence the skeletal muscle task in the context of exercise is less studied. Here, we review recent data about hypothalamus-skeletal muscle crosstalk in response to physical activity and focus on specific aspects such as the neuroendocrinological effects of exercise and the endocrine functions of skeletal muscle, to provide a perspective for future study directions.
Acute and chronic bupropion treatment does not prevent morphine-induced conditioned place preference in mice
2020, European Journal of Pharmacology
Citation Excerpt :
Next, we explored whether an acute injection of bupropion (20 mg/kg, i. p.) administered immediately prior to the CPP test was sufficient to increase dopamine levels in the mouse brain. To do this, we analyzed activity counts in mice treated with bupropion, immediately or 30 min before testing due to the strong correlation between dopamine release and locomotor activity in rodents (Freed and Yamamoto, 1985; Isaacson et al., 1978; Pijnenburg et al., 1976). The 30 min lag time was selected based on the half-life of bupropion in the mouse brain (~39 min) (Suckow et al., 1986).
A substantial barrier to the treatment of Opioid Use Disorder (OUD) is the elevated relapse rates in affected patients, and a significant contributor to these events of relapse is exposure to cues and contexts that are intensely associated with prior drug abuse. The neurotransmitter dopamine plays a key role in reward-related behaviors, and previous studies have illustrated that dopamine hypofunction in periods of abstinence serves to prompt drug craving and seeking. We hypothesized that restoration of dopaminergic signaling could attenuate drug-seeking behaviors. Therefore, we investigated whether use of an FDA-approved drug, bupropion, an inhibitor of the dopamine transporter (DAT), or a dopamine uptake inhibitor with high affinity for DAT, JHW 007, was able to decrease preference for a drug-paired context. In these experiments, mice underwent 5 days of non-contingent morphine (10 mg/kg) exposure in a conditioned place preference (CPP) paradigm. We found that systemic injection of bupropion (20 mg/kg, i. p.) or intracranial injection of JHW 007 into the nucleus accumbens shell did not prevent the expression of morphine CPP. We then investigated whether chronic bupropion treatment (via implanted osmotic pumps) would influence morphine CPP. We observed that chronic bupropion treatment for 21 days following morphine conditioning did not attenuate the prolonged preference for morphine-paired contexts. Overall, with our dose and paradigm, neither acute nor chronic bupropion diminishes morphine CPP. Continued studies should address FDA-approved medications and their potential for recovery in OUD patients.
Modulation of brain stimulation reward and locomotor activity by ionotropic glutamate receptors of the tail of the ventral tegmental area
2020, Behavioural Brain Research
The rostromedial tegmental nucleus also referred to as the tail of the ventral tegmental area (tVTA) contains a cluster of gamma-aminobutyric acid (GABA)ergic neurons that receive dense glutamatergic afferents from the lateral habenula (LHb), and project to dopamine (DA) neurons of the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc). In light of previous evidence implicating glutamate transmission in the regulation of midbrain DA neuronal activity, we first assessed the impact of intra-tVTA microinjection of NBQX (0.8 nmol/side) and PPPA (0.825 nmol/side), respectively AMPA and NMDA receptor antagonists, on reward induced by intracranial self-stimulation (ICSS) and on locomotor activity. Since the tVTA contains a large concentration of mu opioid receptors, additional measures were obtained following microinjection of endomorphin-1 (EM-1, 1 nmol/side) to confirm tVTA placements. Then, using small interfering RNAs (siRNAs), we tested the effect of tVTA downregulation of the GluN1 subunit of the NMDA receptor on reward and locomotor activity. Results show that NBQX, PPPA and EM-1 all enhance reward and locomotor activity, effects that were of different magnitude in rostral and intermediate parts of the tVTA. On the other hand, a reduction in GluN1 subunits used a marked decrease in operant responding for ICSS, but failed to alter ICSS reward and the reward-enhancing effect of PPPA. Our results support a role for the tVTA as a main inhibitory component of DA-dependent behavioral measures, and suggest that tVTA NMDA receptors that modulate reward are most likely expressed on tVTA afferent terminals.

View all citing articles on Scopus

View full text

Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity

Abstract

Europ. J. Pharmacol.

Brain Res.

European J. Pharmacol.

Brain Res.

Neuropharmacology

Biochem. Pharmacol.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Europ. J. Pharmacol.

Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptics and anti-acetylcholine drugs

J. Pharm. Pharmacol.

Effects of oxotremorine and physostigmine on the turnover of dopamine in the corpus striatum and the limbic system

J. Pharm. Pharmacol.

Evidence for dopamine receptor stimulation by apomorphine

J. Pharm. Pharmacol.

Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system

J. Pharm. Pharmacol.

Effecs of apomorphine on self-stimulation behavior

Psychopharmacologia

Excitation-mediating and inhibition-mediating dopamine receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data

Psychopharmacologia

Neuroleptic and non-neuroleptic catalepsy

Arzneim. Forsch.

Dopamine agonist and antagonist activities of piribedil (ET 495) and its metabolites

Naunyn-Schmiedeb. Arch. Pharmacol.